A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 560-mg Tablet Compared to the Four IMBRUVICA 140 mg Capsules

Trial Profile

A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 560-mg Tablet Compared to the Four IMBRUVICA 140 mg Capsules

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2016

At a glance

  • Drugs Ibrutinib (Primary) ; Ibrutinib
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; B cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastrointestinal cancer; Graft-versus-host disease; Hairy cell leukaemia; Lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours; Urogenital cancer; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 02 Dec 2016 Status changed from recruiting to completed.
    • 27 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top